Total Payments
$6,211
2024 Payments
$1,131
Companies
61
Transactions
334
Medicare Patients
6,078
Medicare Billing
$634,279
Payment Breakdown by Category
Food & Beverage$5,907 (95.1%)
Education$204.21 (3.3%)
Consulting$100.00 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,907 | 326 | 95.1% |
| Education | $204.21 | 7 | 3.3% |
| Consulting Fee | $100.00 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $593.24 | 31 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $582.07 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $389.50 | 21 | $0 (2024) |
| Eisai Inc. | $351.93 | 19 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $328.56 | 20 | $0 (2024) |
| Genentech USA, Inc. | $279.93 | 21 | $0 (2023) |
| Lilly USA, LLC | $230.23 | 12 | $0 (2023) |
| Amgen Inc. | $221.67 | 13 | $0 (2023) |
| PFIZER INC. | $211.22 | 15 | $0 (2024) |
| GENZYME CORPORATION | $210.83 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,131 | 50 | AstraZeneca Pharmaceuticals LP ($147.89) |
| 2023 | $1,358 | 61 | Eisai Inc. ($133.31) |
| 2022 | $198.77 | 11 | E.R. Squibb & Sons, L.L.C. ($46.26) |
| 2020 | $316.09 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($93.43) |
| 2019 | $1,057 | 65 | Merck Sharp & Dohme Corporation ($135.60) |
| 2018 | $1,061 | 62 | Novartis Pharmaceuticals Corporation ($216.59) |
| 2017 | $1,088 | 71 | Genentech USA, Inc. ($145.45) |
All Payment Transactions
334 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Rare Disease | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.35 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $31.59 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.36 | General |
| Category: Oncology | ||||||
| 11/07/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.49 | General |
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Oncology | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.87 | General |
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $2.31 | General |
| 09/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Oncology | ||||||
| 09/04/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $17.56 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/12/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Oncology | ||||||
| 07/17/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $27.15 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 1,622 | 6,552 | $254,386 | $105,067 |
| 2022 | 30 | 1,447 | 8,014 | $207,852 | $89,981 |
| 2021 | 31 | 1,555 | 13,960 | $261,998 | $128,032 |
| 2020 | 30 | 1,454 | 12,823 | $540,420 | $311,199 |
Total Patients
6,078
Total Services
41,349
Medicare Billing
$634,279
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 129 | 245 | $49,762 | $21,296 | 42.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 147 | $42,651 | $18,742 | 43.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 48 | 125 | $47,310 | $11,452 | 24.2% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 11 | 16 | $8,977 | $5,759 | 64.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 183 | 546 | $9,963 | $5,630 | 56.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 12 | 2,380 | $9,520 | $5,563 | 58.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 186 | 574 | $8,166 | $4,354 | 53.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 172 | 474 | $7,131 | $3,946 | 55.3% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 11 | 57 | $3,990 | $3,910 | 98.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $8,787 | $3,359 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 59 | $8,385 | $3,295 | 39.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 158 | 318 | $3,582 | $1,875 | 52.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 38 | $7,267 | $1,740 | 23.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 40 | 85 | $2,465 | $1,399 | 56.8% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 39 | 60 | $2,160 | $1,223 | 56.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 27 | 55 | $4,774 | $1,147 | 24.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 15 | 95 | $6,175 | $1,022 | 16.6% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 21 | 114 | $1,920 | $1,020 | 53.1% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 15 | 50 | $1,726 | $901.00 | 52.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 40 | 62 | $1,488 | $828.32 | 55.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 20 | 39 | $1,287 | $724.62 | 56.3% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 34 | 47 | $1,222 | $694.66 | 56.8% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 11 | 43 | $1,260 | $677.31 | 53.8% |
| 82232 | Beta-2 microglobulin (protein) level | Office | 2023 | 21 | 39 | $1,148 | $607.57 | 52.9% |
| 83550 | Iron binding capacity | Office | 2023 | 42 | 69 | $1,035 | $591.33 | 57.1% |
About Dr. Frank Greco, MD
Dr. Frank Greco, MD is a Medical Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497791602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Greco, MD has received a total of $6,211 in payments from pharmaceutical and medical device companies, with $1,131 received in 2024. These payments were reported across 334 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($5,907).
As a Medicare-enrolled provider, Greco has provided services to 6,078 Medicare beneficiaries, totaling 41,349 services with total Medicare billing of $634,279. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Nashville, TN
- Active Since 06/22/2006
- Last Updated 01/24/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1497791602
Products in Payments
- KEYTRUDA (Biological) $438.26
- Lenvima (Drug) $262.65
- OPDIVO (Biological) $220.19
- XTANDI (Drug) $175.18
- MEKINIST (Drug) $167.87
- KISQALI (Drug) $162.17
- GILOTRIF (Drug) $141.82
- FASLODEX (Drug) $125.76
- Abraxane (Drug) $110.23
- AFINITOR (Drug) $108.86
- LIBTAYO (Biological) $105.70
- CALQUENCE (Drug) $96.22
- VERZENIO (Drug) $95.07
- Nexavar (Drug) $92.50
- LYNPARZA (Drug) $90.97
- Halaven (Drug) $89.28
- FOTIVDA (Drug) $87.27
- IBRANCE (Drug) $83.12
- Nubeqa (Drug) $75.39
- IMBRUVICA (Drug) $74.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Nashville
Dana Thompson, M.d, M.D
Medical Oncology — Payments: $578,344
Medical Oncology $578,344
David Spigel, M.d, M.D
Medical Oncology — Payments: $576,692
Medical Oncology $576,692
Johanna Bendell, M.d, M.D
Medical Oncology — Payments: $430,557
Medical Oncology $430,557
Dr. Melissa Johnson, Md, MD
Medical Oncology — Payments: $361,734
Medical Oncology $361,734
Mace Rothenberg, Md, MD
Medical Oncology — Payments: $251,948
Medical Oncology $251,948
Cathy Eng, M.d, M.D
Medical Oncology — Payments: $216,319
Medical Oncology $216,319